These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11906484)

  • 1. Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system.
    Matsui T; Tamaya K; Seki E; Osajima K; Matsumoto K; Kawasaki T
    Clin Exp Pharmacol Physiol; 2002 Mar; 29(3):204-8. PubMed ID: 11906484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption of Val-Tyr with in vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects.
    Matsui T; Tamaya K; Seki E; Osajima K; Matsumo K; Kawasaki T
    Biol Pharm Bull; 2002 Sep; 25(9):1228-30. PubMed ID: 12230125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats.
    Matsui T; Imamura M; Oka H; Osajima K; Kimoto K; Kawasaki T; Matsumoto K
    J Pept Sci; 2004 Sep; 10(9):535-45. PubMed ID: 15473262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depressor effect induced by dipeptide, Val-Tyr, in hypertensive transgenic mice is due, in part, to the suppression of human circulating renin-angiotensin system.
    Matsui T; Hayashi A; Tamaya K; Matsumoto K; Kawasaki T; Murakami K; Kimoto K
    Clin Exp Pharmacol Physiol; 2003 Apr; 30(4):262-5. PubMed ID: 12680844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect.
    Matsui T; Zhu XL; Watanabe K; Tanaka K; Kusano Y; Matsumoto K
    Life Sci; 2006 Nov; 79(26):2492-8. PubMed ID: 16959271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects.
    Kawasaki T; Seki E; Osajima K; Yoshida M; Asada K; Matsui T; Osajima Y
    J Hum Hypertens; 2000 Aug; 14(8):519-23. PubMed ID: 10962520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative action of an angiotensin I-converting enzyme inhibitory peptide, Val-Tyr, via an L-type Ca2+ channel inhibition in cultured vascular smooth muscle cells.
    Toshiro M; Ueno T; Tanaka M; Oka H; Miyamotq T; Osajima K; Matsumoto K
    Hypertens Res; 2005 Jun; 28(6):545-52. PubMed ID: 16231761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
    Hagmann M; Nussberger J; Naudin RB; Burns TS; Karim A; Waeber B; Brunner HR
    J Cardiovasc Pharmacol; 1997 Apr; 29(4):444-50. PubMed ID: 9156352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive effect of peptides from royal jelly in spontaneously hypertensive rats.
    Tokunaga KH; Yoshida C; Suzuki KM; Maruyama H; Futamura Y; Araki Y; Mishima S
    Biol Pharm Bull; 2004 Feb; 27(2):189-92. PubMed ID: 14758031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of 13C stable isotope labeling liquid chromatography-multiple reaction monitoring-tandem mass spectrometry method for determining intact absorption of bioactive dipeptides in rats.
    Nakashima EM; Kudo A; Iwaihara Y; Tanaka M; Matsumoto K; Matsui T
    Anal Biochem; 2011 Jul; 414(1):109-16. PubMed ID: 21377441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M; Chatellier G; Guyene TT; Ménard J
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
    Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
    Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.
    Flesch G; Müller P; Lloyd P
    Eur J Clin Pharmacol; 1997; 52(2):115-20. PubMed ID: 9174680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive mechanism of the dipeptide Val-Tyr in rat aorta.
    Vercruysse L; Morel N; Van Camp J; Szust J; Smagghe G
    Peptides; 2008 Feb; 29(2):261-7. PubMed ID: 18221823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.
    Jackson B; Cubela R; Johnston CI
    J Hypertens; 1984 Aug; 2(4):371-7. PubMed ID: 6099390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
    Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of antihypertensive small peptides, Val-Tyr and Ile-Val-Tyr, by fluorometric high-performance liquid chromatography combined with a double heart-cut column-switching technique.
    Ueno T; Tanaka M; Matsui T; Matsumoto K
    Anal Sci; 2005 Aug; 21(8):997-1000. PubMed ID: 16122175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the clinical pharmacology of enalapril.
    Davies RO; Gomez HJ; Irvin JD; Walker JF
    Br J Clin Pharmacol; 1984; 18 Suppl 2(Suppl 2):215S-229S. PubMed ID: 6099737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.